en · de · es · fr · pt
aod-9604-notes.peptides6579.com › Guide › Background And Research Context — Field Notes

Background And Research Context — Field Notes

By Editorial Desk · published 2025-07-29 · last reviewed 2025-09-09 · Guide

anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-09. Anything still debated is marked as such rather than presented as settled.

Background And Research Context

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Related pages on this site

Identity and Molecular Context

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Supporting material

The 20S proteasome is both ubiquitous and essential in eukaryotes and archaea. The bacterial order Actinomycetales, also share homologs of the 20S proteasome, whereas most bacteria possess heat shock genes hslV and hslU, whose gene products are a multimeric protease arranged in a two-layered ring and an ATPase. The hslV protein has been hypothesized to resemble the likely ancestor of the 20S proteasome. In general, HslV is not essential in bacteria, and not all bacteria possess it, whereas some protists possess both the 20S and the hslV systems. Many bacteria also possess other homologs of the proteasome and an associated ATPase, most notably ClpP and ClpX. This redundancy explains why the HslUV system is not essential. Sequence analysis suggests that the catalytic β subunits diverged earlier in evolution than the predominantly structural α subunits. In bacteria that express a 20S proteasome, the β subunits have high sequence identity to archaeal and eukaryotic β subunits, whereas the α sequence identity is much lower. The presence of 20S proteasomes in bacteria may result from lateral gene transfer, while the diversification of subunits among eukaryotes is ascribed to multiple gene duplication events.

=== 2023: French Open semifinals, Hamburg title === Zverev returned to the tour for the first time since his ankle injury by participating at the inaugural United Cup where he lost in straight sets to Jiří Lehečka and Taylor Fritz. Seeded 12th at the Australian Open, he won his first match since June 2022 by beating lucky loser, Juan Pablo Varillas, in the first round in five sets. He was defeated in the second round by American and lucky loser, Michael Mmoh, in four sets. After the Australian Open, Zverev represented Germany in the Davis Cup tie against Switzerland. He won his first match over Stan Wawrinka. He lost his second match to Marc-Andrea Hüsler. Switzerland ended up winning the tie over Germany 3–2. Seeded eighth at the Rotterdam Open, he was eliminated from the tournament in the second round by Dutch wildcard, Tallon Griekspoor, in three sets. Seeded fourth at the Qatar ExxonMobil Open, he fell in the second round to wildcard, former world No. 1, two-time champion, and eventual finalist, Andy Murray. In March, he played at the Dubai Championships. Seeded seventh, he reached the semifinals where he lost to second seed, defending champion, and eventual finalist, Andrey Rublev. Zverev began his early U.S. hard court campaign at the Indian Wells Masters. Seeded 12th, he reached the fourth round but lost to fifth seed, world No. 6, and eventual finalist, Daniil Medvedev, in three close sets. Seeded 13th at the Miami Open, he was beaten in the second round by wildcard Taro Daniel. Zverev began his clay-court season at the Monte-Carlo Masters.

== Examples of major bioenergetic processes == Glycolysis is the process of breaking down glucose into pyruvate, producing two molecules of ATP (per 1 molecule of glucose) in the process. When a cell has a higher concentration of ATP than ADP (i.e. has a high energy charge), the cell cannot undergo glycolysis, releasing energy from available glucose to perform biological work. Pyruvate is one product of glycolysis, and can be shuttled into other metabolic pathways (gluconeogenesis, etc.) as needed by the cell. Additionally, glycolysis produces reducing equivalents in the form of NADH (nicotinamide adenine dinucleotide), which will ultimately be used to donate electrons to the electron transport chain. Gluconeogenesis is the opposite of glycolysis; when the cell's energy charge is low (the concentration of ADP is higher than that of ATP), the cell must synthesize glucose from carbon- containing biomolecules such as proteins, amino acids, fats, pyruvate, etc. For example, proteins can be broken down into amino acids, and these simpler carbon skeletons are used to build/ synthesize glucose. The citric acid cycle is a process of cellular respiration in which acetyl coenzyme A, synthesized from pyruvate dehydrogenase, is first reacted with oxaloacetate to yield citrate. The remaining eight reactions produce other carbon-containing metabolites. These metabolites are successively oxidized, and the free energy of oxidation is conserved in the form of the reduced coenzymes FADH2 and NADH.

Sources: en.wikipedia.org

Supporting material

Around 1980, Geneviève Meurgues conserved the hull of the Roman boat found under the construction site of the Stock Exchange shopping center in Marseille, using freeze-drying and resinous injection techniques. The conserved boat is on display at the Marseille History Museum.In 1985 she was awarded the Prix Jean-Perrin for her work to popularise science. From 1988, she devoted herself to the development of grande galerie de l'évolution du Muséum national d'histoire naturelle at the National Museum of Natural History. She worked on the choice of specimens, the interpretation and writing of scientific texts and the synopses and screen plays for documentary films, as well as designing games for the gallery. Meurgues was promoted to professor of the Museum in 1992. The grande galerie de l'évolution was opened on 21 June 1994, the day of the summer solstice, by President François Mitterrand. Meurgues escorted him through the gallery. Geneviève Meurgues worked as the deputy director of the Grande Galerie de l'Évolution until her retirement in 1998.

Advanced product quality planning is a process developed in the late 1980s by a commission of experts who gathered around the 'Big Three' of the US automobile industry: Ford, GM, and Chrysler. Representatives from the three automotive original equipment manufacturers (OEMs) and the Automotive Division of American Society for Quality Control (ASQC) created the Supplier Quality Requirement Task Force for developing a common understanding on topics of mutual interest within the automotive industry. This commission worked five years to analyze the then-current automotive development and production status in the US, Europe, and especially in Japan. At the time, the Japanese automotive companies were successful in the US market. APQP is utilized by US automakers and some of their affiliates. Tier 1 suppliers are typically required to follow APQP procedures, techniques, and are also typically required to be audited and registered to IATF 16949. This methodology is also being used in other manufacturing sectors. The Automotive Industry Action Group (AIAG) is a non-profit association of automotive companies founded in 1982. The basis for the process control plan is described in AIAG's APQP manual These include:

One of the main roles of the INO80 subfamily is the incorporation and removal of alternate histones in the nucleosome. In the presence of the H2A.Z histone, the INO80 subfamily of remodelers catalyze the repositioning and eventual removal of this alternate histone. The H2A.Z histone is found on the first nucleosome at the beginning of genes. The INO80 subfamily of remodelers will also be recruited to the H2A.X histone in the homologous recombination repair pathway. In addition to this function, the INO80 subfamily plays a role in transcriptional regulation and genomic recombination. In the DNA damage pathways, the INO80 subfamily aids in repair, recombination, and cell cycle regulation. The INO80 subfamily can activate the recruitment of replication checkpoint factors and can aid in the recovery from replicative stress on the DNA strand. The subfamily's ability to incorporate alternate histones is important for genome stability, disease pathogenesis, and stem cell identity. INO80 complexes commonly bind to nucleosome free regions at transcription start sites and termination sites. INO80 is the only remodeler that is able to use the energy from ATP hydrolysis to create nucleosome free regions and cooperate with other remodelers to equally space nucleosomes.

Emission of neutrons during the fission of uranium is important not only for maintaining the nuclear chain reaction, but also for the synthesis of the heavier actinides. Uranium-239 converts via β-decay into plutonium-239, which, like uranium-235, is capable of spontaneous fission. The world's first nuclear reactors were built not for energy, but for producing plutonium-239 for nuclear weapons. About half of produced thorium is used as the light-emitting material of gas mantles. Thorium is also added into multicomponent alloys of magnesium and zinc. Mg-Th alloys are light and strong, but also have high melting point and ductility and thus are widely used in the aviation industry and in the production of missiles. Thorium also has good electron emission properties, with long lifetime and low potential barrier for the emission. The relative content of thorium and uranium isotopes is widely used to estimate the age of various objects, including stars (see radiometric dating). The major application of plutonium has been in nuclear weapons, where the isotope plutonium-239 was a key component due to its ease of fission and availability. Plutonium-based designs allow reducing the critical mass to about a third of that for uranium-235. The "Fat Man"-type plutonium bombs produced during the Manhattan Project used explosive compression of plutonium to obtain significantly higher densities than normal, combined with a central neutron source to begin the reaction and increase efficiency. Thus only 6.2 kg of plutonium was needed for an explosive yield equivalent to 20 kilotons of TNT.

Sources: en.wikipedia.org

Notes from published material

Like most KWS institute directors, Haber had accrued a large discretionary fund. It was his wish that it be distributed to the dismissed staff to facilitate their emigration. Hahn brokered a deal whereby 10 per cent of the funds would be allocated to Haber's people and the rest to KWS, but the Rockefeller Foundation insisted that the funds be used for their original scientific research or else be returned. In August 1933 the administrators of the KWS were alerted that several boxes of Rockefeller Foundation-funded equipment were about to be shipped to Herbert Freundlich, one of the department heads that Hahn had dismissed, who was now working in England. Ernst Telschow, a Nazi Party member, was in charge while Planck, the president of the KWS since 1930, was on vacation, and he ordered the shipment halted. Hahn complied, but he disagreed with the decision on the grounds that funds from abroad should not be diverted to military research, which the KWS was increasingly undertaking. When Planck returned from vacation, he ordered Hahn to expedite the shipment. Haber died on 29 January 1934. A memorial service was held on the first anniversary of his death. University professors were forbidden to attend, so they sent their wives in their place. Hahn, Planck and Joseph Koeth attended, and gave speeches. The ageing Planck did not seek re-election, and was succeeded in 1937 as president by Carl Bosch, a winner of the Nobel Prize in Chemistry and the chairman of the board of IG Farben, a company which had bankrolled the Nazi Party since 1932. Telschow became Secretary of the KWS.

=== Fasciacyte === A fasciacyte is a type of biological cell that produces hyaluronan-rich extracellular matrix and modulates the gliding of muscle fasciae. Fasciacytes are fibroblast-like cells found in fasciae. They are round-shaped with rounder nuclei and have less elongated cellular processes when compared with fibroblasts. Fasciacytes are clustered along the upper and lower surfaces of a fascial layer. Fasciacytes produce hyaluronan, which regulates fascial gliding.

A positive diagnosis test for thiamine deficiency involves measuring the activity of the enzyme transketolase in erythrocytes (erythrocyte transketolase activation assay). Alternatively, thiamine and its phosphorylated derivatives can directly be detected in whole blood, tissues, foods, animal feed, and pharmaceutical preparations following the conversion of thiamine to fluorescent thiochrome derivatives (thiochrome assay) and separation by high-performance liquid chromatography. Capillary electrophoresis techniques and in-capillary enzyme reaction methods have emerged as alternative techniques in quantifying and monitoring thiamine levels in samples. The normal thiamine concentration in EDTA-blood is about 20–100 μg/L.

Blumofe (1930), producer of Bound for Glory, nominated for the Academy Award for Best Picture Ben Maddow (1930), screenwriter for The Asphalt Jungle, God's Little Acre and The Mephisto Waltz Albert Maltz (1930), screenwriter for Destination Tokyo and one of the Hollywood Ten Arnold M. Auerbach (1932), Primetime Emmy Award-winning American comedy writer William Ludwig (1932), Academy Award-winning screenwriter, Interrupted Melody Martin Manulis (1935), CBS television and movie producer, Days of Wine and Roses, The Best of Broadway, Climax!, Suspense; creator of Playhouse 90; former president of 20th Century Fox Television Charles H. Schneer (1940), film producer known for his collaboration with Ray Harryhausen I.A.L. Diamond (1941), screenwriting partner of Billy Wilder; co-author of Some Like It Hot; co-winner of the Academy Award for Best Original Screenplay for The Apartment Don M.

=== Indirect size measurement of intact complexes === Sedimentation-velocity analytical ultracentrifugation (measures the translational diffusion constant) Dynamic light scattering (measures the translational diffusion constant) Pulsed-gradient protein nuclear magnetic resonance (measures the translational diffusion constant) Fluorescence polarization (measures the rotational diffusion constant) Dielectric relaxation (measures the rotational diffusion constant) Dual polarisation interferometry (measures the size and the density of the complex) Methods that measure the mass or volume under unfolding conditions (such as MALDI-TOF mass spectrometry and SDS-PAGE) are generally not useful, since non-native conditions usually cause the complex to dissociate into monomers. However, these may sometimes be applicable; for example, the experimenter may apply SDS-PAGE after first treating the intact complex with chemical cross-link reagents.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Network